Canada approves two generic Ozempic
- Health Canada cleared Apotex’s generic semaglutide on May 1, days after approving Dr. Reddy’s version on April 28, giving Canada two Ozempic copycats. - Canada says it is the first G7 country to approve generic semaglutide, and Health Canada is still reviewing eight more applications from other companies. - The approvals matter because Canadian generics often cost 45% to 90% less than branded drugs.
Semaglutide is the active ingredient in Ozempic — the diabetes drug that also became a cultural phenomenon because of weight-loss demand. The problem has been simple: huge demand, high prices, and one brand dominating supply. This week, Canada moved first among G7 countries and approved not one but two generic versions. Dr. Reddy’s got the first green light on April 28, 2026, and Apotex got the second on May 1, 2026. (canada.ca) ### What actually got approved? These are generic semaglutide injections that reference Ozempic, not some looser “similar” copy. Health Canada cleared Dr. Reddy’s submission as an abbreviated new drug submission tied to Ozempic as the Canadian reference product, then app(canada.ca)kly semaglutide ingredient people already know from the brand drug. (canada.ca) ### Why is Canada suddenly first? Basically, Canada got an opening that other big markets did not. Semaglutide’s Canadian protection expired earlier, which created room for generic filings before the U.S. or Europe opened up in the same way. That is why Health Canada cou(canada.ca)is also a patent-timing story. (canada.ca) ### Does this mean cheap Ozempic right away? Cheaper, probably. Cheap overnight, not necessarily. Health Canada points out that generic medicines in Canada are often 45% to 90% less expensive than brand-name versions, which is the headline everyone notices. But approval (canada.ca)ually reliable. So the price pressure is real, but the speed of savings will depend on rollout. (canada.ca) ### Why does a second approval matter so much? One generic is a crack in the wall. Two starts to look like a market. Apotex matters because it is the first Canadian-based company approved for a generic equivalent of Ozempic, which gives the story a domestic manufacturing angle (canada.ca) of those clear, Novo Nordisk stops competing with one challenger and starts competing with a category. (apotex.com) ### Is this about diabetes or weight loss? Officially, these approvals are for type 2 diabetes. That matters because Ozempic’s medical indication is diabetes care, even though semaglutide became famous far bey(apotex.com)ll get messier — especially if demand from people focused on weight management keeps spilling over. (canada.ca) ### What does this mean for Novo Nordisk? It means Canada just became an early stress test for the branded GLP-1 business. Ozempic is still a blockbuster, and brand loyalty plus supply relationships do not vanish in a week. But once generics arrive, the logic changes. Pa(canada.ca)the brand to hold premium pricing. (money.usnews.com) ### So what is the bottom line? Canada did not just approve another diabetes drug. It opened the door to a generic semaglutide market before any other G7 country, and it did it twice in one week. If launches happen smoothly, this could be the moment Ozempic in Canada starts shifting from scarce blockbuster to ordinary drug category — still important, but finally contestable. (canada.ca)
